TY  - JOUR
T1  - Ege Üniversitesi Hastanesinde renal kanser hastalarının epidemiyolojisi ve genel sağ kalım özellikleri
TT  - Epidemiological and overall survival characteristics of kidney cancer patients in Ege University Hospital database
AU  - Gürsoy, Pınar
AU  - Çakar, Burcu
AU  - Gökmen, Erhan
AU  - Sarsık Kumbaracı, Banu
AU  - Şen, Sait
AU  - Apaydın, Erdal
AU  - Çal, A. Çağ
AU  - Caner, Ayse
AU  - Özkök, Serdar
AU  - Haydaroğlu, Ayfer
PY  - 2019
DA  - December
DO  - 10.19161/etd.669480
JF  - Ege Tıp Dergisi
JO  - EJM
PB  - Ege University
WT  - DergiPark
SN  - 1016-9113
SP  - 133
EP  - 139
LA  - tr
AB  - Amaç: Ege Üniversitesi Hastanesinde 1992-Haziran 2018 arası kanser tanısı konan ve tedavisiyapılan renal kanser tanılı hastaların genel özellikleri, tedavi modaliteleri ve sağ kalım sürelerinintanımlanması amaçlanmıştır.Gereç ve Yöntem: Ege Üniversitesi Kanserle Savaş Araştırma ve Uygulama Merkezi tarafındantoplanan renal kanser verileri CANREG özel bilgisayar programına kayıt edilmiş, DSÖ ve SEERsistemleri temelinde gruplanarak analizler yapılmıştır. İstatistik analizlerde Fisher’s Exact Test,KaplanMeier sağ kalım analizleri uygulanmıştır. Sağ kalım analizinde Log Rank (Mantel-Cox), Breslow(Generalized Wilcoxon) ve Tarone-Ware istatistikleri kullanılmıştır. İstatistik analizlerde p
KW  - Böbrek kanseri
KW  - epidemiyoloji
KW  - insidans
KW  - genel sağ kalım.
N2  - Aim: The purpose of this study was to describe the general characteristics, treatment modalities andoverall survival times of kidney cancer patients that diagnosed and treated in between 1992 –andJune 2018 at Ege University Hospital.Materials and Methods: Ege University Cancer Control, Research and Application Centerregistered the collected kidney cancer data in CANREG which is a special computer program forgrouping and analyzing the data in WHO and SEER based systems. Fisher’s Exact Test KaplanMeier survival analyzing technique was used in statistical analysis. Log Rank(Mantel-Cox),Breslow(Generalized Wilcoxon) and Tarone-Ware statistical techniques were used in survivalanalysis. P
CR  - SEER Stat Fact Sheets: Kidney and Renal Pelvis. http://seer.cancer.gov/statfacts/html/kidrp.html .
CR  - Störkel S,van den Berg E. Morphological classification of renal cancer. World J Urol. 1995;13(3):153-8.
CR  - Israel GM, Bosniak MA. How I do it: evaluating renal masses. Radiology, 236 (2), 441-50.
CR  - Johnson CD, Dunnick NR, Cohan RH, Illescas FF. Renal adenocarcinoma: CT staging of 100 tumors. AJR Am
J Roentgenol, 148 (1), 59-63.
CR  - Koga S, Tsuda S, Nishikido M et al. The diagnostic value of bone scan in patients with renal cell carcinoma. J
Urol, 166 (6), 2126-8.
CR  - Ramdave S, Thomas GW, Berlangieri SU et al.Clinical role of F-18 fluorodeoxyglucose positron emission
tomography for detection and management of renal cell carcinoma. J Urol. 2001 Sep;166(3):825-30.
CR  - Novara G, Martignoni G, Artibani W, Ficarra V. Grading systems in renal cell carcinoma. J Urol. 2007
Feb;177(2):430-6.
CR  - Cheville JC, Lohse CM, Zincke H et al. Comparisons of outcome and prognostic features among histologic
subtypes of renal cell carcinoma. Am J Surg Pathol. 2003 May;27(5):612-24.
CR  - Kassouf W, Sanchez-Ortiz R, Tamboli P et al. Cytoreductive nephrectomy for metastatic renal cell carcinoma
with nonclear cell histology. . J Urol. 2007 Nov;178(5):1896-900. Epub 2007 Sep 17.
CR  - Motzer RJ, Hutson TE, Tomczak P et al. Overall survival and updated results for sunitinib compared with
interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009 Aug 1;27(22):3584-90. doi:
10.1200/JCO.2008.20.1293. Epub 2009 Jun 1.
CR  - Rini BI, Halabi S, Rosenberg JE et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa
monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. . J Clin Oncol.
2010 May 1;28(13):2137-43. doi: 10.1200/JCO.2009.26.5561. Epub 2010 Apr 5.
UR  - https://doi.org/10.19161/etd.669480
L1  - https://dergipark.org.tr/en/download/article-file/915954
ER  -